| Activating HER2 mutations in HER2 gene amplification negative breast cancer R Bose, SM Kavuri, AC Searleman, W Shen, D Shen, DC Koboldt, ... Cancer discovery 3 (2), 224-237, 2013 | 888 | 2013 |
| Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts S Li, D Shen, J Shao, R Crowder, W Liu, A Prat, X He, S Liu, J Hoog, C Lu, ... Cell reports 4 (6), 1116-1130, 2013 | 678 | 2013 |
| HER2 activating mutations are targets for colorectal cancer treatment SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ... Cancer discovery 5 (8), 832-841, 2015 | 294 | 2015 |
| Proteogenomic integration reveals therapeutic targets in breast cancer xenografts K Huang, S Li, P Mertins, S Cao, HP Gunawardena, KV Ruggles, ... Nature communications 8 (1), 14864, 2017 | 151 | 2017 |
| The prognostic effects of somatic mutations in ER-positive breast cancer OL Griffith, NC Spies, M Anurag, M Griffith, J Luo, D Tu, B Yeo, J Kunisaki, ... Nature communications 9 (1), 3476, 2018 | 125 | 2018 |
| Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95-and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death … SM Kavuri, P Geserick, D Berg, DP Dimitrova, M Feoktistova, D Siegmund, ... Journal of Biological Chemistry 286 (19), 16631-16646, 2011 | 110 | 2011 |
| HER2 missense mutations have distinct effects on oncogenic signaling and migration DJ Zabransky, CL Yankaskas, RL Cochran, HY Wong, S Croessmann, ... Proceedings of the National Academy of Sciences 112 (45), E6205-E6214, 2015 | 92 | 2015 |
| HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor NE Ben-Baruch, R Bose, SM Kavuri, CX Ma, MJ Ellis Journal of the National Comprehensive Cancer Network 13 (9), 1061-1064, 2015 | 89 | 2015 |
| Loss of MutL disrupts CHK2-dependent cell-cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer S Haricharan, N Punturi, P Singh, KR Holloway, M Anurag, J Schmelz, ... Cancer discovery 7 (10), 1168-1183, 2017 | 75 | 2017 |
| Tobacco-specific carcinogens induce hypermethylation, DNA adducts, and DNA damage in bladder cancer F Jin, J Thaiparambil, SR Donepudi, V Vantaku, DWB Piyarathna, S Maity, ... Cancer Prevention Research 10 (10), 588-597, 2017 | 70 | 2017 |
| Sustained JNK activation in response to tumor necrosis factor is mediated by caspases in a cell type-specific manner A Wicovsky, N Muller, N Daryab, R Marienfeld, C Kneitz, S Kavuri, ... Journal of biological chemistry 282 (4), 2174-2183, 2007 | 64 | 2007 |
| Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression V Vantaku, V Putluri, DA Bader, S Maity, J Ma, JM Arnold, K Rajapakshe, ... Oncogene 39 (40), 6265-6285, 2020 | 49 | 2020 |
| Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation M Neumann, S Klar, A Wilisch-Neumann, E Hollenbach, S Kavuri, ... Oncogene 30 (21), 2485-2492, 2011 | 40 | 2011 |
| The contact allergen nickel sensitizes primary human endothelial cells and keratinocytes to TRAIL‐mediated apoptosis M Schmidt, M Hupe, N Endres, B Raghavan, S Kavuri, P Geserick, ... Journal of Cellular and Molecular Medicine 14 (6b), 1760-1776, 2010 | 27 | 2010 |
| Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer NB Punturi, S Seker, V Devarakonda, A Mazumder, R Kalra, CH Chen, ... Nature communications 12 (1), 2940, 2021 | 15 | 2021 |
| Thioredoxin reductase is a major regulator of metabolism in leukemia cells S Karunanithi, R Liu, Y Hou, G Gonzalez, N Oldford, AJ Roe, N Idipilly, ... Oncogene 40 (33), 5236-5246, 2021 | 14 | 2021 |
| Poziotinib inhibits HER2-mutant–driven therapeutic resistance and multiorgan metastasis in breast cancer R Kalra, CH Chen, J Wang, AB Salam, LE Dobrolecki, A Lewis, C Sallas, ... Cancer Research 82 (16), 2928-2939, 2022 | 9 | 2022 |
| Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer LD Eli, SM Kavuri Cancer Drug Resistance 5 (4), 873, 2022 | 3 | 2022 |
| The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer CS Amara, KR Kami Reddy, Y Yuntao, YS Chan, DWB Piyarathna, ... Nature Communications 15 (1), 1373, 2024 | | 2024 |
| The uncharted role of HER2 mutant alleles in breast cancer R Kalra, B Lim, MJ Ellis, SM Kavuri Oncotarget 14, 904, 2023 | | 2023 |
Ron BoseAssociate Professor of Oncology, Washington University School of MedicineVerified email at dom.wustl.edu
